Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NNI 351

Next Previous
Drug Profile

NNI 351

Alternative Names: NNI-351

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuronascent
  • Class Anxiolytics; Behavioural disorder therapies; Small molecules
  • Mechanism of Action DYRK kinase inhibitors; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder; Down syndrome; Fragile X syndrome; Post-traumatic stress disorders

Most Recent Events

  • 10 Sep 2025 NNI 351 is still in preclinical trials for Down syndrome, Post-traumatic stress disorders, Fragile X syndrome, Attention-deficit hyperactivity disorder in USA (PO) (Neuronascent pipeline, September 2025)
  • 01 Jun 2022 NNI 351 receives Orphan Drug status for Fragile X syndrome in USA
  • 01 Jun 2022 Pharmacodynamics data from preclinical studies in Fragile X syndrome released by Neuronascent

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top